Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003

被引：0
|
作者：
Wang, Zhan [1 ]
Zhao, Yang [1 ]
Zhang, Yushi [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China
来源：
EUROPEAN UROLOGY | 2022年 / 81卷 / 05期
关键词：
D O I：
10.1016/j.eururo.2022.01.047
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E120 / E120
页数：1
相关论文
共 50 条
  • [1] Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j. eururo.2020.04.038 Cytoreductive Nephrectomy: To Whom and When?
    Mollica, Veronica
    Rizzo, Alessandro
    Massari, Francesco
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (04): : 559 - 560
  • [2] Re: Alexander Cox, Niklas Klumper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi. org/10.1016/j.eururo.2023.03.020
    Hoglund, Mattias
    Lund Bladder Canc Grp
    [J]. EUROPEAN UROLOGY, 2023, 84 (02)
  • [3] Re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012
    Lv, Meng
    Luo, Xufei
    Chen, Yaolong
    [J]. EUROPEAN UROLOGY, 2022, 82 (04) : E118 - E118
  • [4] Reply to Mattias Hoglund's Letter to the Editor re: Alexander Cox, Niklas Klumper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
    Kluemper, Niklas
    Cox, Alexander
    Eckstein, Markus
    [J]. EUROPEAN UROLOGY, 2023, 84 (02) : E51 - E52
  • [5] Re: Yu Xiao, Kaiyu Qian, Yongwen Luo, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.025
    He, Peng
    Wang, Xiaohui
    Li, Hao
    [J]. EUROPEAN UROLOGY, 2020, 78 (01) : E25 - E26
  • [6] Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
    Torras, Oscar Reig
    Mishra, Akhilesh
    Christie, Alana
    McKenzie, Tiffani
    Onabolu, Oreoluwa
    Singla, Nirmish
    Plimack, Elizabeth R.
    Suarez, Cristina
    Ornstein, Moshe C.
    Alpaugh, R. Katherine
    Elias, Roy
    Bowman, I. Alex
    McKay, Renee M.
    Przybycin, Christopher
    Kapur, Payal
    Brugarolas, James
    Rini, Brian
    [J]. EUROPEAN UROLOGY, 2022, 81 (06) : 555 - 558
  • [7] Re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021
    Singh, Kirti
    Mandal, Swarnendu
    Das, Manoj Kumar
    Nayak, Prasant
    Tripathy, Sambit
    [J]. EUROPEAN UROLOGY, 2023, 83 (06)
  • [8] Re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. In press. https://doi.org/10.1016/j. eururo.2023.11.012
    Singh, Jas
    [J]. EUROPEAN UROLOGY, 2024, 86 (03) : e73 - e73
  • [9] Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
    Vickers, Andrew J.
    [J]. EUROPEAN UROLOGY, 2024, 86 (03) : e71 - e71
  • [10] Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
    Giuliani, Jacopo
    Bonetti, Andrea
    [J]. EUROPEAN UROLOGY, 2018, 73 (03) : E74 - E74
12345